These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19902521)

  • 21. Recent advances in osteosarcoma.
    Botter SM; Neri D; Fuchs B
    Curr Opin Pharmacol; 2014 Jun; 16():15-23. PubMed ID: 24632219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
    Li Z; Peng H; Xu Q; Ye Z
    J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant interferon treatment of human osteosarcoma.
    Strander H; Aparisi T; Blomgren H; Broström LA; Cantell K; Einhorn S; Ingimarsson S; Nilsonne U; Söderberg G
    Recent Results Cancer Res; 1982; 80():103-7. PubMed ID: 6173900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
    Kaehler KC; Sondak VK; Schadendorf D; Hauschild A
    Eur J Cancer; 2010 Jan; 46(1):41-6. PubMed ID: 19857957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma.
    Bernthal NM; Federman N; Eilber FR; Nelson SD; Eckardt JJ; Eilber FC; Tap WD
    Cancer; 2012 Dec; 118(23):5888-93. PubMed ID: 22648705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells.
    Okamoto T; Yamada N; Tsujimura T; Sugihara A; Nishizawa Y; Ueda H; Kashiwamura S; Tsutsui H; Futani H; Maruo S; Okamura H; Terada N
    J Interferon Cytokine Res; 2004 Mar; 24(3):161-7. PubMed ID: 15035849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: a comparison of results obtained in single-institution and multicenter trials.
    Bacci G; Mercuri M; Longhi A; Setola E; Gozzi E; Forni C
    Chir Organi Mov; 2004; 89(4):283-92. PubMed ID: 16048049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.
    Ferrari S; Palmerini E
    Curr Opin Oncol; 2007 Jul; 19(4):341-6. PubMed ID: 17545797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alpha interferons--new therapeutic modalities].
    Bajcetić M; Zigon N; Samardzić R; Beleslin DB
    Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experiences and perspectives on adjuvant chemotherapy in osteogenic osteosarcoma].
    Jasmin C; Delépine G; Delépine N; Trifaud A; Mathé G
    Biomed Pharmacother; 1986; 40(5):167-9. PubMed ID: 3466653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma.
    Moore C; Eslin D; Levy A; Roberson J; Giusti V; Sutphin R
    Pediatr Blood Cancer; 2010 Dec; 55(6):1096-102. PubMed ID: 20734401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunity against tetanus and diphtheria after childhood sarcoma treatment.
    Paulides M; Stöhr W; Laws HJ; Graf N; Lakomek M; Berthold F; Schmitt K; Niggli F; Jürgens H; Bielack S; Koscielniak E; Klingebiel T; Langer T
    Klin Padiatr; 2010 May; 222(3):196. PubMed ID: 20514629
    [No Abstract]   [Full Text] [Related]  

  • 34. Melanoma: therapeutic options with recombinant interferons.
    Kirkwood JM; Ernstoff M
    Semin Oncol; 1985 Dec; 12(4 Suppl 5):7-12. PubMed ID: 2417333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Adjuvant chemotherapy for osteosarcoma in Japan--past, present and future].
    Furuse K; Maeyama I; Morimoto K; Orito T
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1746-56. PubMed ID: 6591859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New targets and approaches in osteosarcoma.
    Gill J; Ahluwalia MK; Geller D; Gorlick R
    Pharmacol Ther; 2013 Jan; 137(1):89-99. PubMed ID: 22983152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon therapy in neoplastic diseases.
    Strander H; Einhorn S
    Philos Trans R Soc Lond B Biol Sci; 1982 Sep; 299(1094):113-7. PubMed ID: 6183685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biological activity of human alpha-interferons studied using specific antisera].
    Korsun NS; Nosik DN; Novokhatskiĭ AS; Trushinskaia GN
    Antibiot Khimioter; 1988 Nov; 33(11):827-30. PubMed ID: 2465745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon therapy in neoplastic disease. A preliminary report.
    Christophersen IS; Jordal R; Osther K; Lindenberg J; Pedersen PH; Berg K
    Acta Med Scand; 1978; 204(6):471-6. PubMed ID: 282780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-viral and anti-neoplastic actions of interferon--with special reference to its clinical application].
    Imanishi J
    Nihon Rinsho; 1980 Sep; 38(9):3272-81. PubMed ID: 6166771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.